Target Name: IL17B
NCBI ID: G27190
Review Report on IL17B Target / Biomarker Content of Review Report on IL17B Target / Biomarker
IL17B
Other Name(s): IL17B variant 1 | interleukin 20 | NIRF | Interleukin-17B | IL-17B | Interleukin-17B (isoform 1) | Neuronal interleukin-17-related factor | ZCYTO7 | Cytokine Zcyto7 | interleukin-17 beta | neuronal interleukin-17 related factor | interleukin 17B | Interleukin-20 | IL17B_HUMAN | IL-20 | cytokine-like protein ZCYTO7 | Interleukin 17B, transcript variant 1

IL17B: Potential Drug Target and Biomarker

IL17B (Interleukin-17B) is a cytokine that plays a crucial role in the immune response and inflammation. It is produced by various immune cells, including T cells, and is involved in the regulation of cellular processes such as cell growth, differentiation, and survival. IL17B has also been shown to have a number of potential drug targets and biomarkers.

One of the key functions of IL17B is its role in the regulation of immune cell function. IL17B has been shown to promote the production and activation of CD4+ T cells, which are a key component of the immune system. It has also been shown to play a role in the regulation of CD8+ T cell function, with studies showing that IL17B can either promote or inhibit the activity of these cells depending on the specific context.

IL17B has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of the inflammatory response, with studies showing that IL17B can either promote or inhibit the production of pro-inflammatory cytokines. This may have implications for the treatment of inflammatory disorders such as rheumatoid arthritis, where inflammation is a key factor.

IL17B has also been shown to have potential as a biomarker for certain diseases. For example, studies have shown that IL17B levels can be elevated in individuals with rheumatoid arthritis, with higher levels of IL17B often being associated with greater disease severity. Additionally, IL17B has been shown to be elevated in individuals with other inflammatory disorders, such as diabetic ketoacidosis. This may suggest that IL17B could be a useful biomarker for the diagnosis and treatment of these disorders.

Despite the potential benefits of IL17B as a drug target and biomarker, much more research is needed to fully understand its role in the immune and inflammatory systems. Many studies that have investigated IL17B have focused on its effects on specific cell types or specific cytokines, rather than its more general functions. Additionally, there is a need for more research to determine the optimal method for diagnosing and treating IL17B-related disorders.

In conclusion, IL17B is a cytokine that has been shown to play a crucial role in the immune and inflammatory systems. Its potential as a drug target and biomarker for the treatment of a variety of disorders makes it an important area of research for the future. Further studies are needed to fully understand its role and potential as a therapeutic agent.

Protein Name: Interleukin 17B

Functions: Stimulates the release of tumor necrosis factor alpha and IL-1-beta from the monocytic cell line THP-1

The "IL17B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL17B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4